Imine-Oxazoline (ImOx): A C1-Symmetric N,N-Bidentate Ligand for Asymmetric Catalysis

11 December 2024, Version 2
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Asymmetric catalysis relies on the design of chiral ligands, but the variety of nitrogen-based ligands remains limited To address this gap, we have developed a class of C1-symmetric N,N-bidentate ligand, imine-oxazoline (ImOx), derived from amino acids through a four-step synthesis. ImOx features an imine moiety conjugated with a chiral oxazoline ring, as a hybrid of α-diimine (ADI) and pyridine oxazoline (PyOx) ligands. Its low symmetry allows for independent optimization at both coordination sites. ImOx improves the enantioselectivity of palladium-catalyzed conjugate addition reactions, demonstrating a strong correlation between ee and the steric effects on both the imine and oxazoline sites. Studies on well-defined organopalladium intermediates reveal that the steric bulk of ImOx necessitates a cationic pathway to promote alkene insertion. Structural characterization if ImOx suggests a stronger trans-influence compared to PyOx. Moreover, ImOx demonstrates excellent redox activity, promoting the reduction of nickel complexes and stabilizing nickel radical complexes. We anticipate that ImOx will expand the toolkit of chiral N-ligands for asymmetric catalysis.

Keywords

Chiral ligand
ImOx
Asymmetric conjugation addition
Redox activity
electrochemical potentials

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
All experimental procedures, additional figures, details of compound synthesis, characterization, EPR, UV-Visible spectra NMR spectra, details of DFT calculations, spin density plots.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.